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“he Heart Failure Society of America (HFSA) is the
eading professional society that provides a multidisciplinary
orum for a diverse group of health care professionals
nvolved in basic, clinical, and translational research, patient
are, and public policy about heart failure. The HFSA
ctively promotes and facilitates education and training
fforts through the development of comprehensive and
ontinuously updated patient care guidelines, a program for
oung trainee physicians pursuing careers in academic med-
cine, patient education materials, and public awareness.
hrough the development of position reports and partici-
ation in collaborative working groups, the HFSA serves as
resource for government, providers, and industry on issues
f mutual interest including the design of clinical trials for
rugs and devices for heart failure.
Most recently, on September 22, 2008, the American
oard of Medical Specialties approved the American Board
f Internal Medicine proposal to establish a secondary
ubspecialty certification in Advanced Heart Failure and
ransplant Cardiology. The certification will establish stan-
ards and competencies for cardiologists with the experi-
nce necessary to treat patients with advanced or complex
resentations of heart failure syndrome.
The 12th Annual Scientific Meeting, cochaired by Drs.
andeep R. Mehra and Howard A. Rockman was attended
y approximately 2,300 health care professionals including
ardiologists, surgeons, nurses, pharmacists, and other allied
ealth professionals representing academia, government,
nd industry. Presentations covered topics in basic, transla-
ional, and clinical research, as well as clinical care and
ublic policy. Topics were addressed in a variety of formats,
rom the *University of Maryland School of Medicine, Baltimore, Maryland; †Duke
niversity, Durham, North Carolina; and the ‡University of California at San Diego,
an Diego, California. Dr. Mehra has received research grants from the NIH,
aryland Industrial Partnerships Agency, State of Maryland Other Tobacco Related
iseases fund, and Orqis, and is a consultant to Orqis, Roche, Astellas, Celladon,
laxoSmithKline, Geron, Debio Pharma, Solvay, Novartis, Medtronic, Scios, Boston
cientific, and St. Jude. Dr. Rockman is a consultant and co-scientific founder of
revena, Inc. Dr. Greenberg has served as a consultant to AstraZeneca, Celladon,
laxoSmithKline, NitroMed, Otsuka, ARCA Biopharma, and Orqis Medical; and
erived honoraria from AstraZeneca, GlaxoSmithKline, Medtronic, Merck, Ni-e
roMed, Novartis, and Scios.
Manuscript received October 24, 2008 and accepted November 3, 2008.ncluding symposia, award competitions, oral abstract ses-
ions, how-to sessions, debates, and moderated posters.
his article provides a brief overview of some of the new,
nnovative and interesting topics covered.
xcellence in Basic Science
r. Louis J. Ignarro, corecipient of the 1998 Nobel Prize in
hysiology and Medicine, delivered the second Distin-
uished Lecture in Basic Science entitled “Nitric Oxide as a
nique Signaling Molecule in Physiology.” In his lecture he
rovided a historical perspective of the discovery of nitric
xide and discussed the effects on cardiovascular disease
hen nitric oxide signaling is dysregulated. Dr. Ingarro’s
ecture was followed by other presentations describing new
esearch on the basic molecular mechanisms of heart failure.
pening Session: Aerobiology,
he Environment, and Cardiovascular Health
n a departure from tradition, the opening plenary session
ocused on global public health to prevent heart failure with
peakers addressing environmental aspects of cardiovascular
isease. Salim Yusuf (McMaster University, Hamilton,
ntario, Canada) addressed heart disease from a global
erspective with a particular focus on the role of urbaniza-
ion in his talk on “Metabolic Syndrome: A Detriment to
ocietal Evolution.” Urbanization is associated with auto-
ation, decreased physical activity, and increased energy
onsumption especially of fats in addition to increased levels
f psycho-social stress. The result is an increase in the
revalence of obesity, dyslipidemia, dysglycemia, hyperten-
ion, and other markers of heart disease. The major differ-
ntiating risk factor for cardiovascular disease is not ethnic-
ty but how and where you live, said Dr. Yusuf who
nderscored that the world is urbanizing quickly. In 1970,
ne-third of the world’s population lived in urban settings.
y 2025, it is expected to increase to 60%. “Therefore, the
oot cause of heart disease is not biology but is sociology.”
We need to understand both the benefits and adverse
ffects on health of urbanization,” Dr. Yusuf said.
p
b
4
l
i
i
h
U
C
i
P
s
D
H
G
O
e
s
c
b
w
“
t
r
w
s
f
W
h
H
c
t
p
m
v
a
c
t
w
b
a
c
m
i
e
K
h
i
o
i
i
L
B
l
2
w
3
m
V
G
H
o
h
p
a
m
s
d
d
c
i
m
m
c
p
o
w
r
t
h
s
w
b
u
p
w
s
m
t
l
d
1
P
a
p
M
E
M
M
t
n
u
t
515JACC Vol. 53, No. 6, 2009 Mehra et al.
February 10, 2009:514–22 HFSA 2008 Meeting HighlightsTo reduce the global risk of heart disease in high-risk
opulations, he advocated increased efforts to reduce to-
acco use and more widespread use of a polypill containing
simple, cost-effective drugs: aspirin, a beta-blocker, a
ipid-lowering drug, and an angiotensin-converting enzyme
nhibitor. Implementation of these measures is suboptimal
n the U.S. let alone in other parts of the world.
Richard J. Jackson, visiting professor of environmental
ealth sciences at the School of Public Health at the
niversity of California at Los Angeles, Los Angeles,
alifornia, discussed a related consequence of urbanization
n his talk, “Tackling the Obesity Epidemic through Urban
lanning.” “A failed environment equals failed health,”
aid Dr. Jackson, a pediatrician who formerly served as
irector of the National Center for Environmental
ealth for the Centers for Disease Control, Atlanta,
eorgia, and as the California State Public Health
fficer. The way we have constructed our homes and
nvironment is the leading cause of these problems, he
aid. “The environment is rigged against people.”
We supersize schools and site them way out of town, so
hildren have to sit on school buses instead of walking or
iking to school. We give patients pedometers, and they do
ork somewhat. But you have to give people a place to walk.
It’s time for doctors to speak up more aggressively against
his rigging of the environment. We need to create envi-
onments that allow people to be healthy,” said Dr. Jackson
ho cited examples in California where health care profes-
ionals have worked actively with government officials to
acilitate land use that supports increased physical activity.
Joel D. Kaufman (University of Washington, Seattle,
ashington) addressed a different aspect of environmental
ealth in his talk “Particulate Matter Air Pollution and
eart Health.” Particulate matter air pollution, which is
urrently a main research target, not only has respiratory
oxicity but is clearly related to premature mortality and in
articular cardiovascular mortality. Particulate matter, com-
only referred to as soot, is emitted either directly by
ehicles or from products of combustion or indirectly from
tmospheric chemical reactions. The fact that air pollution
an kill has been established by historical episodes such as
he London smog that occurred in December 1952 during
hich particle levels reached 3,000 g/m3 and which has
een linked to 12,000 excess deaths. Since then, large cohort
nd time-series studies have consistently established in-
reased mortality related to particulate matter. Increased
ortality has been shown with the kind of exposures people
n the U.S. experience everyday and not just the elevated
xposures associated with the most polluted cities, Dr.
aufman said. Additionally, several studies show increased
eart failure hospitalizations related to short-term increases
n air pollution. The exact mechanism of action remains an
pen question and potentially includes remote mediators of
nflammation and oxidative stress leading either directly or
ndirectly to endothelial dysfunction and myocardial effects. vate-Breaking Trials
ecause of the number and quality of submissions, 2
ate-breaking trial sessions were held for the first time at the
008 Annual Scientific Meeting. Four of the 8 trials that
ere presented are summarized here.
,5 diiothyropropionic acid (DITPA): a thyroid hor-
one analog to treat heart failure: phase II trial
eterans’ Administration Cooperative Study. Steven
oldman (Southern Arizona Veterans’ Administration
ealth Care System, Tucson, Arizona) presented the results
f the DITPA trial, which studied the ability of the thyroid
ormone analog DITPA to improve clinical outcomes in
atients with heart failure (1). It has been known for
pproximately 30 years that thyroid hormone can switch
yosin heavy chain V1 and V3. In animal studies and a
mall 19-patient trial, DITPA increased cardiac output and
ecreased vascular resistance and left ventricular end-
iastolic pressure as well as increased angiogenesis with no
hange in myocardial oxygen consumption or heart rate.
The phase II DITPA trial was a multicenter, random-
zed, placebo-controlled, escalating dose study with a pri-
ary composite end point that included heart failure
orbidity and mortality, change in New York Heart Asso-
iation (NYHA) functional class, and the change in global
atient assessment. Secondary end points included a variety
f cardiac and biochemical measures. A total of 86 patients
ith NYHA functional class II to IV heart failure were
andomized 2:1 to receive an escalating dose of DITPA (90
o 360 mg/day) over 8 weeks until thyroid-stimulating
ormone dropped to 0.02 m/l or placebo. Patients were
tudied at 2, 4, 6, 8, 16, and 24 weeks and at 28 weeks, 4
eeks after the drug had been stopped.
The study was prematurely stopped in October 2006,
ecause of slow recruitment, adverse effects (44% discontin-
ed study drug), and futility. The composite primary end
oint showed a tendency toward worsening heart failure
ith DITPA, primarily driven by patient global assessment
cores. However, there were no differences in heart failure
orbidity and mortality and in tachyarrhythmia between
he 2 study groups. Both total cholesterol and low-density
ipoprotein cholesterol dropped in the DITPA group. Ad-
itionally, patients in the DITPA group lost an average of
1 lbs while the placebo group experienced no weight loss.
redictors of clinical success to continuous aortic flow
ugmentation in heart failure exacerbation refractory to
harmacological therapy: analysis of the multicenter
OMENTUM (Orqis Medical Cancion System for the
nhanced Treatment of Heart Failure Unresponsive to
edical Therapy) trial. Mandeep Mehra (University of
aryland, Baltimore, Maryland) presented the results of
his study assessing aortic flow therapy involving a percuta-
eously placed device attached to an extracorporeal centrif-
gal pump that delivers a flow of approximately 1.5 l/min to
he descending aorta (2). The device, which is not a left
entricular assist device (LVAD) in the traditional sense, is
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HFSA 2008 Meeting Highlights February 10, 2009:514–22esigned to correct abnormal flow within the aorta, Dr.
ehra said. The MOMENTUM study was a multi-
enter, randomized study. This post-hoc analysis of the
OMENTUM data evaluated baseline clinical, laboratory,
nd hemodynamic predictors that correlated with post-
ischarge success with medical therapy versus aortic flow
herapy. Success was defined as hospital discharge with no
eadmission for heart failure, alternative mechanical sup-
ort, or death within 35 days.
The MOMENTUM trial enrolled a total of 168 patients
ith chronic heart failure who were hospitalized for decom-
ensation and who were not responding adequately to
herapy with intravenous inotropes, vasodilators, and diuret-
cs and who had a pulmonary capillary wedge pressure 20
m Hg; a cardiac index2.4 l/min/m2 and creatinine1.2
g/dl; or were receiving 120 mg/day of intravenous
urosemide. Patients were randomized to aortic flow therapy
nd background medications or medications alone for 4 days
ith 109 patients in the device therapy and 59 in the control
roup. The patient population was one of the sickest
opulations ever enrolled in a decompensated heart failure
rial, said Dr. Mehra. Most were on at least 1 inotrope, and
0% of patients had died within 2 months.
Results of the study found that the device improved left
entricular performance in the aortic-flow device group as
emonstrated by an increase in the cardiac index and
eduction in left-sided filling pressures. Multivariate sub-
roup analysis found that a combination of nonischemic
tiology, blood-urea-nitrogen levels 32 mg/dl, and
-terminal pro-B-type natriuretic peptide levels 5,200
g/ml identify patients in the MOMENTUM study pop-
lation in whom aortic-flow therapy demonstrated an in-
remental clinically significant benefit of 23% when com-
ared with the control group. Dr. Mehra noted that 21% of
he patient population in the MOMENTUM study popu-
ation met these criteria. These data pointed out that
atients with the more severe hemodynamic perturbations
ut less advanced heart failure comorbidity may derive the
ost benefit from aortic-flow therapy. Dr. Clyde Yancy,
aylor Medical Center, Dallas, Texas, commented that
hese data were post hoc and thus could represent a play of
hance and should be proven in further trial populations.
esults of the COMPARE (Multicenter, Randomized,
ouble-Blind, Double-Dummy, Parallel Group Study
o Compare Effects of Coreg CR and Coreg IR on Left
entricular and Systolic Volume Index in Subjects With
table Chronic Heart Failure) trial. Barry H. Greenberg
University of California at San Diego, San Diego, Califor-
ia) presented the results of the COMPARE trial, a
rospective, multicenter, double-blind, double-dummy,
oninferiority study in which the immediate release (IR)
ormulation of carvedilol was compared with a controlled
elease (CR) formulation (3). Randomized controlled trials
ave demonstrated that carvedilol IR has beneficial effects to
everse maladaptive left ventricular remodeling and improve
utcomes in patients with chronic heart failure. The initial arimary end point of change in left ventricular ejection
raction (LVEF) was revised to evaluation of change in the
eft ventricular end-systolic volume index as measured with
-dimensional echocardiography due to considerations re-
arding measurement variability and patient dropout rate.
econdary end points included the change in LVEF, change
n left ventricular structure, change in serum B-type natri-
retic peptide, and hospitalizations for heart failure and all
ther causes, all-cause death, drug dose tolerability, and
ompliance.
A total of 318 patients with chronic, mild-to-severe heart
ailure who were on stable, optimal therapy, naïve to
eta-blockers and had an LVEF0.40 were randomized to
ither carvedilol IR or carvedilol CR. Carvedilol IR was
tarted at 3.125 mg twice daily and titrated to a dose of 25
g twice daily. Coreg CR was started at 10 mg daily and
itrated to a maximum daily dose of 80 mg. In the
ouble-dummy design, patients were instructed to take 1
apsule out of bottles labeled A and B in the morning and
capsule out of bottles labeled C and D in the afternoon.
atients were followed for 24 weeks on blinded therapy after
itration. Analysis was based on 253 patients as there was an
8.9% drop-out rate providing 80% power to establish
oninferiority of carvedilol CR. Results of the study found
here was no significant difference between the 2 groups for
he primary end point of left ventricular end-systolic volume
ndex. Similarly, there were comparable changes for impor-
ant secondary end points including LVEF, the left ventric-
lar end systolic volume index, left ventricular wall thick-
ess, biomarkers, and morbidity and mortality measures for
oth preparations. Additionally, there were no significant
ifferences in adverse events. A continuous release prepara-
ion with once-daily administration may beneficially affect
ompliance and further improve outcomes, but this asser-
ion was contested by members who raised concerns about
he increased price tag of such therapy compared with that
f cheap generic carvedilol.
ADHART-CHF (Safety and Efficacy of Sertaline for
epression in Patients With Congestive Heart Fail-
re) trial. Christopher M. O’Connor (Duke University,
urham, North Carolina) presented the results of the
ADHART-CHF trial, which studied the efficacy of ser-
aline, a selective serotonin reuptake inhibitor antidepres-
ant, on depressive symptoms in heart failure (4). Depres-
ion is a common comorbidity and associated with higher
ortality in heart failure patients with a step-wise increase
n risk based on the gradation of depression. The
ADHART-CHF study was a multicenter, randomized,
ouble-blind, placebo-controlled study designed to deter-
ine whether sertaline plus nurse-facilitated intervention
mproves symptoms of depression and/or reduces cardiac
vents to a greater extent than nursing intervention alone.
he primary end points were a change in severity of
epressive symptoms during acute treatment, and the oc-
urrence of worsening cardiovascular status at the end of
cute treatment using a composite end point. Secondary end
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February 10, 2009:514–22 HFSA 2008 Meeting Highlightsoints included scores on a number of rating scales and
ehospitalization. The study is the largest trial of an inter-
ention for depression in heart failure.
A total of 469 patients with chronic systolic heart failure
ho were 45 years old with NYHA functional class II to
V heart failure and an LVEF 45% who had symptoms of
ajor depression were randomized to receive a dosage of 50
g/day of sertaline plus nurse-facilitated supported inter-
ention or placebo and nurse-facilitated intervention. Pa-
ients were followed for 12 weeks in the acute phase of the
rial. The long-term phase with follow-up of up to 5 years
s still ongoing. Patients received telephone calls during
eeks 1, 2, 4, 8, and 10 from nurses with psychiatric
raining and participated in face-to-face meetings at the
linic or in the home during weeks 6 and 12. Women and
inority patients were well represented, and there was a
igh rate of diabetes and renal disease. Baseline depression
cores were among the highest seen in a heart failure trial.
esults of the study found no significant differences in
epression scale ratings between the 2 groups. There were
mprovements in both groups, but over 50% of patients
emained depressed at 12 weeks. Similarly, scores on the
omposite cardiovascular end point were equivalent for both
roups. In conclusion, the SADHART-CHF study found
hat sertaline appears to be safe in high-risk patients with
eart failure. Although there were no significant differences
etween the 2 treatment methods, a nurse-facilitated inter-
ention that occurred with both groups may have contrib-
ted to the placebo effect and diminished the ability to
bserve differences between the groups, emphasizing the
mportance of a nurse-based intervention in heart failure.
ebates
s the heart failure continuum (prevention to destina-
ion) best managed in the U.S.? Harlan M. Krumholz
Yale University, New Haven, Connecticut) and Paul W.
rmstrong (University of Alberta, Edmonton, Alberta,
anada) faced off in a debate over which country provides
he best patient care for heart failure. Dr. Krumholz
cknowledged that, although free and universal health
overage in Canada is a remarkable accomplishment, this
pproach did not result in better care for heart failure
atients. Waiting for care is an issue in Canada compared
ith that in the U.S. The median waiting time for cathe-
erization outpatients in Hamilton, Ontario, is 60 days,
oting that the city is close to the U.S. border, but wait
imes can be longer in more remote areas. Waiting can have
onsequences, he asserted. Furthermore, in Canada 15%
f patients are seen by a cardiologist, while in the U.S. more
han 25% receive care from a cardiologist. Additionally,
anada has a slow adoption of technology compared with
he U.S., citing implantable cardioverter-defibrillator usage
y example. Dr. Krumholz also noted the risk/treatment
aradox in Canada, whereby the highest-risk patients areeast likely to be treated with lifesaving heart failure drugs. cn a review of mortality data, the U.S. held an advantage at
0 days, while 1-year results were about the same. Better
hort-term survival, shorter wait times, and more access to
pecialists and technology favor heart failure patients in the
.S., he concluded.
Dr. Armstrong argued superior performance on preven-
ion and public health initiatives supports heart failure
atient care in Canada. Cost and access to health care are
ssues in the U.S. with 42% of Americans either unin-
ured or underinsured. In terms of meeting guideline-
ecommended care for heart failure such as control of
ypertension, Dr. Armstrong pointed out the poor compli-
nce in the U.S. where treatment and control is 40%. The
ecord is not only better in Canada but also in Cuba, a
ountry with far fewer resources than in the U.S. In another
easure of cardiac risk factors, obesity is prolific in the U.S.
imilarly, he cited poor results in quality performance
easures such as percentage of hospitalized heart failure
atients given explanations for their medications or pro-
ided with discharge instructions. Primary and secondary
revention provides the best return on investment. Al-
hough the U.S. is faster on the uptake of new technologies,
n the end the overall advantage goes to Canada, Dr.
rmstrong concluded.
hould an endomyocardial biopsy be performed in most
eart failure patients? In presenting the case for endomyo-
ardial biopsy in heart failure patients, James B. Young
Cleveland Clinic, Cleveland, Ohio) reframed the question
o exclude ischemic etiology for which a biopsy would not
dd much information. Those patients aside, Dr. Young
aid a biopsy can provide valuable information about pa-
hology that can then be addressed appropriately. Addition-
lly, the causes of nonischemic heart failure are heteroge-
eous, and we must know the diagnosis before talking to the
atient about their etiology. A biopsy can also provide
nformation on hypertrophy, fibrosis, and immunohistolog-
cal changes important to prognosis. It is a safe, well-
olerated, and easy-to-perform procedure. It helps plan
reatment, Dr. Young concluded.
In contrast, Stephen S. Gottlieb (University of Maryland,
altimore, Maryland) argued that endomyocardial biopsy
hould only be used in selected cases since only 1% of
atients have a biopsy that provides useful information. Dr.
ottlieb also pointed out that although the risk is small,
here is still a risk in performing the procedure and it is not
egligible. Risks include perforation, tricuspid valve regur-
itation, and death among others. Biopsies are unreliable,
nd even if a biopsy demonstrates prognosis, it will have
inimal impact on the treatment plan. Most biopsies will
rovide information that you will not do anything about.
he facts are not there now, he concluded.
eading Clinical Research
romoting research related to all aspects of heart failure is
ritical to the mission of the HFSA. Leading clinical
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HFSA 2008 Meeting Highlights February 10, 2009:514–22esearch abstracts were divided into 2 oral abstract sessions.
he sessions provided a forum for investigators to present
esearch on leading-edge topics. In the first session, Gregory
. Hartlage (University of South Florida, Tampa, Florida)
resented data on discontinuation of the chemotherapeutic
gent trastuzumab due to cardiotoxic effects.
Dr. Hartlage’s talk was followed by 3 others: Amrut V.
mbardekar (University of Colorado, Denver, Colorado)
resented data from the Get With the Guidelines–Heart
ailure registry on outcomes for nonadherent patients; Greg
onarow (University of California at Los Angeles, Los
ngeles, California) presented on whether quality of care
nd outcomes differed for patients hospitalized on the
eekend; and Wayne C. Levy (University of Washington,
eattle, Washington) presented the Seattle Heart Failure
odel and how it is used to identify risk stratification of
atients for an LVAD. In the second session Michael
ristow (University of Colorado, Denver, Colorado) pre-
ented on the agonist binding exhibited by human myocar-
ial preparations with differing genotypes and their selective
nactivation by bucindolol; Christian Zellner (University of
alifornia at San Francisco, San Francisco, California),
ecipient of a 2007 to 2008 HFSA Research Fellowship,
resented the results of his research on the gene variants
aveolin-1 and caveolin-2 in patients with idiopathic pul-
onary arterial hypertension; Gautam G. Lalani (University
f California at San Diego, San Diego, California) pre-
ented on action potential dynamics and arrhythmic suscep-
ibility in systolic heart failure; and Lisa C. Costello-
oerrigter (Mayo Clinic, Rochester, Minnesota) concluded
he session with a presentation on a polymorphism of the
-type natriuretic peptide associated with a higher preva-
ence of type 2 diabetes and atrial fibrillation.
ovel Interventions in Heart Failure: A New Age?
ovel techniques reflecting new approaches to the treat-
ent of heart failure were addressed in a session that
xamined applications of gene therapy, nitric oxide scav-
nge, and device therapy.
Roger J. Hajjar (Mount Sinai School of Medicine, New
ork, New York) discussed gene therapy targeting sarco-
lasmic reticulum Ca2 ATPase (SERCA2a), which is
mportant in maintaining calcium homeostasis in cardiomy-
cytes. SERCA2a activity is decreased in failing human
earts. Pharmacological targeting of SERCA2a has failed,
nd multiple large-scale efforts have been abandoned. Res-
uing SERCA2a via gene transfer has been shown to
mprove cardiac contractility and calcium handling in car-
iac myocytes in patients with heart failure. In a rodent
odel, overexpression of SERCA2a was associated with
urther favorable cardiovascular effects including a decrease
n ventricular arrhythmias and cardiac hypertrophy, an
mproved energetic profile, and an increase in coronary flow.number of clinical trials have been developed to study tose escalation of SERCA2a in heart failure patients, as
ell as studies researching new vectors and targets.
Frank W. Smart (Gagnon Cardiovascular Institute, Mor-
ison, New Jersey) presented on the role of nitric oxygen
cavengers in the treatment of cardiogenic shock of ischemic
tiology. Current treatment involves stabilizing blood pres-
ure, reperfusing tissue, and supporting the patient through
he use of inotropes, pressors, and mechanical circulation
nd ventilation. Despite these measures, cardiogenic shock
fter acute myocardial infarction (MI) continues to be a
ajor cause of mortality. There is evidence that there are
imilarities between the pathophysiology of cardiogenic
hock and other types of shock such as septic and anaphy-
actic shock and that an excessive systemic inflammatory
esponse including an increase in nitric oxide is involved.
r. Smart, however, noted that nitric oxide is a double-
dged sword with both positive and negative impacts on
ardiovascular function. Recent studies examining the affect
f nitric oxide inhibition in patients with cardiovascular
ysfunction have demonstrated this dual function. Nonse-
ective nitric oxide inhibition was found to increase blood
ressure but did not reduce 30-day mortality in a large
linical trial. He surmised the results were due to the helpful
nd harmful aspects of nitric acid. Animal data indicate that
itric oxide scavengers may prove more advantageous than
ompletely blocking nitric acid production. However, he
oncluded, human data are needed to determine whether
his approach results in a mortality benefit.
Philip B. Adamson (Oklahoma Heart Hospital, Oklahoma
ity, Oklahoma) opened his presentation on implantable
ressure sensors and their application in the management of
eart failure by asking participants to first consider whether
emodynamic monitors were even needed (5). Even in the best
f hands, physical examination is specific but not very sensitive.
emodynamic monitoring may, therefore, provide needed
nformation. Dr. Adamson went on to review 3 types of
mplantable hemodynamic monitors in advanced clinical de-
elopment: those that provide continuous assessment, noncon-
inuous assessment, and hemodynamic monitors that are inte-
rated into other devices such as an implantable cardioverter-
efibrillator or biventricular pacemaker. Although there is no
efinitive clinical study confirming the value of such hemody-
amic monitors, there have been signals as to which types of
atient would benefit the most. In the COMPASS-HF
Chronicle Offers Management to Patients With Advanced
igns and Symptoms of Heart Failure) trial, there were
ndications that monitoring would be better suited in nonstage
refractory heart failure patients. Conversely, hemodynamic
onitoring is of little value in trying to manage volume in
atients with advanced renal disease. We are still learning how
o work with these devices. Michael R. Zile (Medical Univer-
ity of South Carolina, Charleston, South Carolina) concluded
he session with a presentation on investigational devices for
eart failure with a preserved ejection fraction (50%). Dr.
ile discussed 4 devices: an implantable hemodynamic moni-or, baroreceptor stimulation, a device designed to augment
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February 10, 2009:514–22 HFSA 2008 Meeting Highlightsiastolic recoil, and chronotropic incompetence pacing. He
lso reviewed ongoing clinical studies of these devices regard-
ng application to diastolic heart failure. He concluded that
hese devices and studies present the possibility of device
herapy for diastolic heart failure or will at least generate
estable hypotheses.
alvular Disease in Heart Failure
urrent thinking in regard to the treatment of valve
ysfunction in heart failure patients was addressed in this
ession that touched upon mitral regurgitation (MR),
ortic valve disease, and the possibilities of less invasive
ntervention.
Todd M. Koelling (University of Michigan, Ann Arbor,
ichigan) discussed MR in heart failure and various assess-
ent methods. The severity of MR has strong prognostic
alue in terms of survival of patients with systolic heart
ailure. Transthoracic echocardiography is the preferred
maging method of determining the severity of MR. The
onvergence zone on the proximal side of the mitral valve,
he vena contracta, and the jet can all be visualized with
olor flow Doppler and used to assess MR severity. Dr.
oelling noted that eccentricity, the Nyquist limit, and
pectral consistency are among the factors that must be
aken into account when using echocardiography to assess
R severity. Additionally, pulmonary vein inflow, rever-
eration, excessive gain, and reverse timing of the signal
mong others can result in echocardiography images that
an confuse assessment when using echocardiography.
road-beam spectral Doppler, which allows for both narrow
nd broad beam assessment and provides velocities for the
ntire regurgitant orifice area, may be used in the future for
ore refined assessment of MR. For patients that do not
ave good echocardiography windows, catheterization and
agnetic resonance imaging provide alternative assessment
ools. With all of the focus on imaging MR, Dr. Koelling
nderscored the need to ensure that the patient is receiving
ptimal medical therapy as medications can change the
egree of MR with time.
Robert C. Gorman (University of Pennsylvania, Phila-
elphia, Pennsylvania) focused on the surgical treatment of
ischemic” MR, defined as a mitral valve with normal
eaflets and chordae tendinae that is rendered incompetent
ue to left ventricular remodeling after an MI. Approxi-
ately 19% of patients have some MR early after an MI,
nd 15% of heart failure patients have severe MR. Any
egree of MR after an MI has negative prognostic impli-
ations with longevity decreasing as the degree of MR
ncreases. The favored surgical approach involves placement
f an undersized annuloplasty ring, usually concomitant
ith a coronary artery bypass procedure. Dr. Gorman,
owever, noted the limited clinical data assessing the effect
f surgery on longevity in patients with ischemic MR.
vailable studies have not demonstrated a survival benefitrom valve surgery for ischemic MR. The suboptimal results tay be due to recurrent MR, which is a common problem
nd which may also confound the clinical results. More
mportantly, the remodeling stimulus due to ischemic MR
ay be relatively small compared with the MI.
Peter C. Block (Emory University, Atlanta, Georgia) over-
iewed transcatheter approaches to MR therapy. Percutaneous
ptions include a clip that creates a tissue bridge in mitral valve
rifice. A nonrandomized trial has demonstrated that the
evice works and is most useful in patients with degenerative
R. Four other investigational devices have targeted the
oronary sinus as a route to repair the posterior mitral annulus.
reliminary clinical results have been disappointing. Other
ercutaneous devices under investigation include 2 devices
esigned to change the coaptation line in the mitral valve. In
iscussing device therapy for MR in heart failure, Dr. Block
ointed out that it is important to recognize that MR in heart
ailure is not due to valvular disease but due to left ventricular
emodeling. Therefore, another device that can be placed
ither surgically or percutaneously, that decreases the size of the
entricle and causes the mitral leaflets to coapt again by
ushing the posterior portions of the myocardium and mitral
nnulus forward is of particular interest. Remaining to be seen
s whether these devices can provide long-term benefit and
hether eventually percutaneous mitral valve replacement can
ecome a possibility.
Blase A. Carabello (Baylor University, Houston, Texas)
oncluded the session with a presentation addressing various
spects of aortic valve disease in heart failure. Symptoms of
ortic valve disease should be taken very seriously and treated at
he earliest onset with a valve replacement. Aortic regurgitation
nd aortic stenosis are both predictors of poor prognosis. With
ortic regurgitation, an ejection fraction of 50% is too low, and
ntervention should take place before an end-systolic dimen-
ion of 50 mm to protect the ventricles. One of the challenging
ituations is low-gradient aortic stenosis in patients with a low
jection fraction. These patients have severe left ventricular
ysfunction, and pose a high operative risk—26% mortality in
series. However, some of these patients return to completely
ormal ejection fraction. Inotropic challenge may help in the
election of patients who will most benefit from surgery and
xperience less surgical risk, but additional patient selection
ools are needed. With aortic insufficiency, as with other types
f aortic valve dysfunction, earlier treatment is preferred.
owever, even patients with a large ventricle may do well and
hould be considered for surgery. Finally, Dr. Carabello ex-
lained that the availability of percutaneous aortic valve re-
lacement may change the treatment paradigm for aortic valve
isease.
dvanced Heart Failure:
rognosis-Guided Clinical Decision Making
he use of prognostic tools in the treatment of advanced heart
ailure was discussed in the context of ventricular assist devices
VADs), transplantation, and palliative care in a session on the
reatment of advanced heart failure. Douglas S. Lee (University
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redictive modeling from a population-based point of view and
eviewed available prognostic tools. Prognostic models are
eeded to guide clinical decision making and to tailor thera-
eutic care. The HFSA guidelines, for example, include
ecommendations for implantable cardioverter-defibrillator
herapy based on a patient’s predicted survival, so determining
rognosis is needed to provide guideline-based care. He
eviewed a wide array of markers that have been used in
rognostic models for heart failure including comorbidities, left
entricular systolic function, troponin and B-type natriuretic
eptide among a large and growing number of biomarkers and
eart failure hospitalizations, as well as multivariable models.
ew predictors should demonstrate incremental value beyond
outine clinical models.
Randall C. Starling (Cleveland Clinic, Cleveland, Ohio)
iscussed the use of risk stratification models to decide when
VAD should be implanted. In the past, VADs have not
rovided the outcomes that patients and clinicians desire.
ore recent data show a 1-year survival of 56%, which
rops to approximately 31% at 2 years and approximately
7% at 3 years. However, if patients are stratified into low-,
oderate-, and very high-risk groups, outcomes vary sig-
ificantly by risk group. The NYHA functional class, the
resence of inotropic support, the level of cardiogenic shock,
nd a right ventricular risk score have been used as stratifi-
ation criteria. The challenges are to define a patient
opulation that can benefit most from a VAD and deciding
hen to refer a patient for implantation. Dr. Starling said
he Interagency Registry for Mechanically Assisted Circu-
atory Support (INTERMACS) profiles should be used in
eciding whether to implant a VAD in a patient waiting for
transplant and should be avoided in INTERMACS Level
. Similarly, in the case of an inotrope-dependent patient who
s a candidate for a destination LVAD, the device should be
mplanted before INTERMACS level 1. Right ventricular
unction should also be assessed. A randomized trial should be
erformed to determine the benefit of an LVAD versus
edical therapy in inotrope-dependent patients.
Mariell L. Jessup (University of Pennsylvania, Philadel-
hia, Pennsylvania) spoke on risk stratification in heart
ailure patients waiting for transplantation. In the U.S., the
ickest patients get hearts earlier, so Status 2 patients wait a
ong time before transplantation. It is hard to tell patients
hat they have to get really sick before they can be trans-
lanted, but the approach seems to work in terms of
utcomes. No single criterion should be used to decide
hether to transplant a patient. Rather, the entire picture
hould be taken into account, said Jessup who went on to
xplain the use of various criteria to triage patients for
ransplant including exercise assessment, response to med-
cal therapy, body size, hemodynamics, and the patient’s
lood group. Clinical assessment and INTERMACS score
re also important. She said there was almost a bewildering
rray of available predictors and recommended that clini-
ians pick 1 or 2 and strategize how to use them in practice. oowever, she cautioned that there can be a disconnect
etween the patient’s score and their actual status, and that
he patient who is very sick despite their score should be
ollowed closely.
Sarah J. Goodlin (Patient-Centered Education and Re-
earch, Salt Lake City, Utah) addressed the role of palliative
are in the in the context of providing hope in a hopeless
ituation. Research shows that people make decisions re-
arding treatment depending on the likelihood of a certain
utcome. However, physicians are not very comfortable in
iscussing end of life with heart failure patients. Dr.
oodlin discussed skills needed for having “bad news”
onversations with patients. We need to ask what patients
nd their significant others hope for and to address their
oncerns or fears. We also have to change the way we talk
o people about heart failure and redefine heart failure care.
e need to talk about managing heart failure rather than
bout curing the problem. People die after a fight with
ancer, but they “succumb” to heart failure. We have to
ncourage patients to take ownership of their illness and to
ctively engage in optimizing their function, she concluded.
ntegrating Care for Decompensated
eart Failure: The Emergency Department,
ospitalist, and Cardiologist
he role of the hospitalist and the integration of care for
atients hospitalized for decompensated heart failure were
iscussed in a session that also discussed the evolving roles
f the emergency department and cardiologist. Alpesh N.
min (University of California at Irvine, Irvine, California)
iscussed patient care from the perspective of the hospital-
st. Research has demonstrated that hospitalists reduce
ospital costs and length of stay, and decrease readmissions
nd mortality while preserving patient satisfaction. There is
great opportunity for collaboration between hospitalists,
mergency medicine doctors, and cardiologists working
ith heart failure patients. There are opportunities to
ollaborate on quality improvement measures, patient care,
nd education. We need to develop a nimble system with
ffective teams using evidence-based processes for patient
are. If we stay in our silos, we will have trouble meeting the
emand for heart failure management, he concluded.
Uri Elkayam (University of Southern California, Los
ngeles, California) maintained that cardiologists should
lay a central role in the management of patients hospital-
zed for acute decompensated heart failure. Acute decom-
ensated heart failure is a complicated and malignant
isease. Patients hospitalized with acute decompensated
eart failure are among the sickest patients physicians will
ee. The majority of patients will come in with volume
verload, and the management of these patients can be very
hallenging. He reviewed treatment modalities and clinical
vidence regarding their use noting that it takes a special
xpertise to administer certain treatments citing the example
f managing diuretic resistance. Additionally, he said that
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February 10, 2009:514–22 HFSA 2008 Meeting Highlightsltrafiltration is an effective treatment, but it cannot be
erformed by just anyone in the hospital. Similarly, ino-
ropes and vasodilators should be used only in selected
atients. It requires a special expertise to select appropriate
atients and deliver them properly.
Sean Collins (University of Cincinnati, Cincinnati, Ohio)
ecommended that the emergency rooms should be the
tarting point for clinical trials on acute decompensated
eart failure. We should study acute heart failure when it is
cute. The first 6 to 12 h after hospitalization is an
mportant time. Citing the example of dyspnea, Dr. Collins
aid the majority of heart failure patients show early im-
rovement in dyspnea after traditional treatment. There-
ore, if dyspnea is used as an end point in a clinical trial, it
hould be measured early. If measured late, it may represent
unique subset of nonresponders. Additionally, a wide
ange of heart failure patients present to the emergency
epartment. It is important to target the heterogeneity early.
n regard to obstacles to enrolling patients in the emergency
epartment, Dr. Collins cited the following reasons: chaos
n the emergency department, misdiagnosis, and the prob-
em of enrolling acutely ill patients. He went on to cite the
ork of the Emergency Research Group in Acute Heart
ailure, a group of academic health centers where emer-
ency medicine physicians and cardiologists have worked
ogether to overcome these obstacles.
Mihai Gheorghiade (Northwestern University, Chicago,
llinois) concluded the session with a presentation on unmet
eeds and areas for research and collaboration on acute heart
ailure syndrome. No matter how well heart failure patients
espond to therapy during hospitalization, within 3 to 6
onths as many as 50% of the patients will be either rehospi-
alized or dead. Though controversial, Dr. Gheorghiade sup-
orts the hypothesis that heart failure resulting in hospital-
zation is a distinct entity from chronic heart failure, and
hat the poor prognosis may be due to renal injury that
ccurs before, during, and after hospitalization that contrib-
tes to the progression of heart failure. To improve post-
ischarge morbidity and mortality, we need identify patient
rofiles that stratify risk, study the downstream effects of
arly therapy, and develop a road map for post-emergency
epartment patient care in collaboration with the hospitalist
nd cardiologist, he concluded.
eart Failure Guidelines:
pdates and Applications
ince publishing their Comprehensive Heart Failure Prac-
ice Guidelines in 2006, the HFSA established an ongoing
rocess to update the guidelines and increase accessibility
ia a dedicated website among other initiatives. JoAnn
indenfeld (University of Colorado, Denver, Colorado),
FSA Guideline Committee chair, outlined how the
uidelines undergo a systematic review process with the goal
f updating recommendations based on new evidence, and
ow new areas are vetted for inclusion in the guidelines. two areas nearing completion are genetic evaluation of
ardiomyopathy, and prevention and treatment of heart
ailure in patients receiving chemotherapy. Both are ex-
ected to be published in 2009. Four new topics are under
onsideration: palliative care for heart failure patients, re-
erral for and care of patients with VADs, telemonitoring,
nd risk stratification. The issue of patient self-care will be
ddressed in these guidelines as well. This year’s session was
ase-based and focused on evaluation admission criteria for
cute heart failure, genetic evaluation of cardiomyopathy,
eart failure patients receiving anticancer therapy, and
isease management.
Ray E. Hershberger (University of Miami, Miami, Flor-
da) discussed the genetic evaluation of cardiomyopathy. He
oted that the field of genetics differs from other cardiovas-
ular disease, and that the guidelines committee recognizes
hat the standard of evidence differs as well. The guidelines
re designed to be practical to use and are organized by
isease phenotype. Another major focus of the guidelines is
bout family screening and management. Recommenda-
ions include taking a careful family history for 3 or more
enerations for all patients with cardiomyopathy. Addition-
lly, genetic screening is recommended for 1 clearly affected
erson to facilitate family screening and management.
Daniel J. Lenihan (M.D. Anderson Cancer Center,
ouston, Texas) presented on the evaluation of heart failure
atients receiving anticancer therapy. This new guideline
ill include recommendations for the prevention of heart
ailure in survivors of anticancer therapy and for optimal
dentification, prevention, and management of cardiac dis-
ase and heart failure during anticancer therapy. He also
oted that therapy for both cancer and heart failure are
ntricately intertwined at the molecular level.
Debra K. Moser (University of Kentucky, Lexington,
entucky) discussed new factors to consider in disease
anagement. While there has not been a lot of change in
he guidelines for disease management, there is an increased
mphasis on self-care. Self-care is a way of doing disease
anagement in the absence of a formal disease management
rogram. In discussing self-care, it is important to recognize
he complexities involved in patient self-care and factors
hat should be considered to ensure success. Very few
eople are experts at self-care. Knowledge is necessary,
ut patients also need skills in self-care. Clinicians should
lso suspect misconceptions about basic concepts and
ook for factors that interfere with learning. Clinicians
an also work to overcome barriers to self-care by
ddressing treatable causes and engaging family members
nd other informal caregivers.
cknowledgments
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